AFP and neoplasm: More recently, a retrospective study reported that trends in AFP during the first three weeks after initiation of treatment and baseline DCP levels could be used to predict which patients would benefit from first-line ICI-based therapy (45); however, poor outcomes might be incorrectly predicted in cases with tumor marker pseudoprogression.